(Press-News.org) A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell Medicine, University Hospitals Cleveland and Case Western University. The researchers conclude that relying on biopsy grade alone can lead to underestimating disease risk and misclassifying individuals who may benefit from definitive treatment with either surgery or radiation. Biopsies test only small areas of the prostate, so they can miss more advanced or aggressive cancer cells, providing an incomplete picture.
The study, published July 31 in the journal JAMA Oncology, found that one in six men with GG1 category cancer turns out to have intermediate- or high-risk cancer when other clinical features are considered in addition to biopsy results. “We don’t want to miss aggressive cancers that initially present as Grade Group one on biopsy,” said co-senior author Dr. Bashir Al Hussein, an assistant professor of urology and population health sciences at Weill Cornell Medicine. “Such underestimation of risk could lead to undertreatment and poor outcomes.”
The study results could also inform recent discussions on whether to drop the cancer label completely for GG1 tumors. “There is a misunderstanding that ‘low grade’ and ‘low risk’ are the same. Here, we show clearly that they are not,” said co-senior author Dr. Jonathan Shoag, associate professor of urology at Case Western Reserve University and an urologist at University Hospitals Cleveland. “Attempts to rename GG1 are misguided as many patients with GG1 cancers on biopsy have substantial risks of their cancers causing pain and suffering over their lifetime if untreated.”
Accurately Categorizing Risk Guides Treatment
The team drew on data collected between 2010 and 2020 by the National Cancer Institute’s Surveillance, Epidemiology and End Results Program. “This is real-world, contemporary data representing all men diagnosed with prostate cancer across the United States,” said Dr. Al Hussein, who is also a urologist at NewYork-Presbyterian/Weill Cornell Medical Center and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The data included about 300,000 men who were diagnosed with cancer that was localized to the prostate.
Approximately 117,000 of those men had a biopsy that was categorized as GG1. This grade is often used synonymously with a low risk for progression to metastasis, or cancer spreading to other parts of the body. They are usually followed through active surveillance—blood tests to monitor a protein produced by the prostate, additional biopsies and MRI scans. Increasing prostate-specific antigen (PSA) levels in the blood can indicate cancer progression.
But what if some of these men harbored more aggressive prostate cancers than suggested by their biopsy grade alone? Dr. Al Hussein and his colleagues further analyzed the individuals in the GG1 group with their clinical data such as PSA levels and tumor sizes. When all the data were factored in, the researchers discovered that more than 18,000 of these men had higher risk cancers that are often treated with radiation therapy or removal of the prostate (radical prostatectomy).
“Our data show that up to 30 percent of patients who were diagnosed with GG1 but were in the higher risk category underwent active surveillance, which means they were potentially undertreated,” Dr. Al Hussein said.
What’s in a Name
Understanding how cancer classification correlates with clinical outcomes is particularly critical, as some physicians advocate removing the “cancer” label from GG1 prostate cancer, which could reduce anxiety and unnecessary treatment. They argue that most tumors categorized as GG1 grow slowly and rarely spread or cause harm. However, the paper advises that a one-size-fits-all approach is risky.
“There has been an unfortunate conflation of several different terms by some of my colleagues who are trying to rename GG1 cancer,” explained Dr. Shoag. “One is that biopsy GG1 and prostatectomy GG1 are similar, but they are not. As clinicians, we must make decisions based on each patient and his biopsy results in that context.” The data suggesting that GG1 cancers do not spread is based largely on previous studies of prostatectomy specimens, which examined the whole prostate once it was removed.
“A subset of men with low-grade tumors has adverse clinical features that are associated with worse cancer outcomes. We need to better understand this biology, which could help clinicians improve prognosis," said first author Dr. Neal Arvind Patel, assistant professor of clinical urology, an urologist at NewYork-Presbyterian/Weill Cornell Medical Center and a member of the Meyer Cancer Center.
Dr. Al Hussein also sees room for improving how patients are counseled. “We need to find a better way to inform patients about their prognosis when they have GG1 prostate cancer with adverse clinical features,” he said. “As physicians, the responsibility falls on us to educate patients and provide them with the information they need to understand their diagnosis and decide on the best approach for treatment, while continuing to advocate for active surveillance for those who are indeed low risk.”
END
Not all low-grade prostate cancers are low risk
2025-07-31
ELSE PRESS RELEASES FROM THIS DATE:
GLP-1 RAs and risk of nonarteritic anterior ischemic optic neuropathy in older patients with diabetes
2025-07-31
About The Study: This study of Medicare enrollees age 65 or older with type 2 diabetes found an association between semaglutide use and an increased risk of nonarteritic anterior ischemic optic neuropathy. There was risk variation among the glucagon-like peptide-1 receptor agonists (GLP-1 RAs); semaglutide and liraglutide were associated with higher risks.
Corresponding Author: To contact the corresponding author, Kin Wah Fung, MD, email kfung@mail.nih.gov.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2025.2299)
Editor’s ...
The clinical practice guideline update on adult sinusitis emphasizes patient education, shared decision-making, and evidence-based treatment options
2025-07-31
ALEXANDRIA, VA —The American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) published the Clinical Practice Guideline (CPG): Adult Sinusitis Update today in Otolaryngology–Head and Neck Surgery. The purpose of this multidisciplinary guideline is to identify quality improvement opportunities in managing adult sinusitis and to provide explicit and actionable guidance that can be implemented across all clinical practices.
"With sinusitis affecting about one in eight adults in the United States each year, this CPG update empowers both patients and their healthcare providers with ...
Big data begins to crack the cold case of endometriosis
2025-07-31
Big Data Begins to Crack the Cold Case of Endometriosis
Records from millions of patients at UC health centers found correlations between endometriosis, one of the most common diseases in women, and a bounty of other diseases.
Scientists at UCSF have found that endometriosis — a painful chronic disease affecting 10% of women that often goes undiagnosed — often occurs alongside conditions like cancer, Crohn's disease, and migraine.
The research could improve how endometriosis is diagnosed and, ultimately, how it is treated; and it paints the sharpest portrait yet of a condition that is ...
This artificial sweetener could make cancer treatment less effective
2025-07-31
Sucralose is a popular sugar substitute for people who are cutting calories or managing blood sugar levels, but new research by the University of Pittsburgh and UPMC Hillman Cancer Center suggests that the artificial sweetener may not be the best choice for patients undergoing cancer immunotherapy.
Publishing today in Cancer Discovery, a publication of the American Association for Cancer Research, the study found that patients with melanoma and non-small cell lung cancer who consumed high levels of sucralose had worse ...
Light-based listening: Researchers develop a low-cost visual microphone
2025-07-31
WASHINGTON — Researchers have created a microphone that listens with light instead of sound. Unlike traditional microphones, this visual microphone captures tiny vibrations on the surfaces of objects caused by sound waves and turns them into audible signals.
“Our method simplifies and reduces the cost of using light to capture sound while also enabling applications in scenarios where traditional microphones are ineffective, such as conversing through a glass window,” said research team leader Xu-Ri Yao from Beijing ...
Immunoglobulin replacement therapy shows no reduction in serious infections for patients with CLL
2025-07-31
(WASHINGTON, July 31, 2025) — In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.
“This is the first large, real-world study to follow patients with CLL who are regularly receiving immunoglobulin replacement,” said lead study author Sara Carrillo de Albornoz, health economist and a PhD candidate at Monash University in Australia. “Given its high cost and variable use in clinical ...
University of Colorado Anschutz Medical Campus awarded one of the largest clinical trial grants in campus history to lead trauma study
2025-07-31
AURORA, Colo. (July 31, 2025) – The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial—supported by a $29 million grant from Octapharma—to evaluate whether early replacement of fibrinogen, a critical blood clotting mechanism in the body, can improve outcomes for trauma patients experiencing life-threatening bleeding. This investigator-initiated study is one of the largest clinical trial grants in campus history.
The EFFECT Trial (Early ...
Weather-tracking advances are revealing astonishing extremes of lightning
2025-07-31
It was a single lightning flash that streaked across the Great Plains for 515 miles, from eastern Texas nearly all the way to Kansas City, setting a new world record.
“We call it megaflash lightning and we're just now figuring out the mechanics of how and why it occurs,” said Randy Cerveny, an Arizona State University President’s Professor in the School of Geographical Sciences and Urban Planning.
Cerveny and colleagues used space-based instruments to measure the megaflash, which took place during a major thunderstorm in October 2017. Its astonishing horizontal reach surpasses by 38 miles the previous record of 477 miles recorded during ...
Grasses are spendthrifts, forests are budgeters, in a nuanced account of plant water use
2025-07-31
(Santa Barbara, Calif.) — Even a toddler knows that plants need water. It’s perhaps the first thing we learn about these green lifeforms. But how plants budget this resource varies considerably. The kapok trees of the Amazon have adopted vastly different strategies than the switchgrass of the American plains. Unfortunately, it’s hard to directly measure which ones prevail in different ecosystem types and how they shift under changing conditions.
Researchers at UC Santa Barbara and San Diego State University recently developed a metric ...
"Scrumping" windfallen fruits and the origin of feasting
2025-07-31
The lives of our earliest hominin ancestors are often shrouded in mystery, but recent research on the consumption of windfallen fruit may shed light on one of humanity's oldest and most savored activities: sharing a good meal (and a tipple) with kith and kin.
In a "Notes from the Field" article in the journal BioScience, Nathaniel Dominy (Dartmouth College), Catherine Hobaiter (University of St Andrews), and colleagues coin a new term for gathering and eating fallen fruit: scrumping. The term calls to mind scrumpy, a rustic unfiltered cider popular in the West Country of England. And just as ...